Specialists at information analytics company Elsevier recently announced that its 2017 season for “The Hive,” its source for rising biotech and pharmaceutical companies, is gearing up with unlimited nomination spots now open for aspiring entrants.
Elsevier launched The Hive last year to shed light on an emerging industry pattern indicating that startups can be pivotal to scientific discovery.
“This trend is continuing in 2017 — many of the most promising drug candidates and discoveries in R&D pipelines originate from these early stage companies," Tamas Szarvas, Elsevier's chief medical officer for corporate R&D solutions, said. “The Hive offers a far-reaching platform for sharing success stories."
Hive members will be able to reach milestones more quickly. Participants from 2016 vouched for the program’s advantages, citing exposure and training opportunities leading to increased productivity and breakthroughs.
“Participation has provided us with an amazing array of resources," said Tom Wickham, who serves as R&D vicepresident at Rubius Therapeutics, a 2016 member.
Pre-revenue biotech, pharma and other small companies involved in early stage research with at least 10 scientists on staff are eligible for application and enrollment. Elsevier evaluates candidates following completion of a questionnaire, goal review and phone interviews and will select at least eight companies.
From its hub in Amsterdam, Netherlands, Elsevier helps to advance science, health care and performance with solutions for research, R&D, education and more.